Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
45.1M
-
Number of holders
-
87
-
Total 13F shares, excl. options
-
24.2M
-
Shares change
-
-381K
-
Total reported value, excl. options
-
$366M
-
Value change
-
-$5.52M
-
Number of buys
-
44
-
Number of sells
-
-32
-
Price
-
$15.13
Significant Holders of Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share (YMAB) as of Q2 2022
98 filings reported holding YMAB - Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q2 2022.
Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share (YMAB) has 87 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 24.2M shares
of 45.1M outstanding shares and own 53.59% of the company stock.
Largest 10 shareholders include BlackRock Inc. (2.98M shares), Polar Capital Holdings Plc (2.95M shares), ALLIANCEBERNSTEIN L.P. (2.82M shares), Sofinnova Investments, Inc. (2.19M shares), FMR LLC (1.97M shares), VANGUARD GROUP INC (1.93M shares), WELLINGTON MANAGEMENT GROUP LLP (1.87M shares), STATE STREET CORP (1.74M shares), GEODE CAPITAL MANAGEMENT, LLC (626K shares), and BIOIMPACT CAPITAL LLC (444K shares).
This table shows the top 87 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.